The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin

Biomaterials

Volumn 34, Issue 9, 2013, Pages 2277-2288

  Fan, Yuchen ^a   Du, Wenwen ^a   He, Bing ^a   Fu, Fengying ^a   Yuan, Lan ^b   Wu, Hounan ^b   Dai, Wenbing ^a   Zhang, Hua ^a   Wang, Xueqing ^a   Wang, Jiancheng ^a   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Combination therapy; Doxorubicin; Imatinib; Intratumoral delivery; Sterically stabilized liposome; Tumor interstitial fluid pressure

Indexed keywords

COMBINATION THERAPY; DOXORUBICIN; IMATINIB; INTERSTITIAL FLUID PRESSURES; INTRATUMORAL DELIVERY; STERICALLY STABILIZED LIPOSOMES;

CELL CULTURE; CHEMOTHERAPY; DRUG PRODUCTS; ONCOLOGY;

TUMORS;

DOXORUBICIN; IMATINIB; LIPOSOME; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD TOXICITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARDIOTOXICITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FIBROBLAST; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE PRESSURE; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL PROLIFERATION; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; EXTRACELLULAR FLUID; FEMALE; FIBROBLASTS; IMMUNOHISTOCHEMISTRY; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NIH 3T3 CELLS; PIPERAZINES; POLYETHYLENE GLYCOLS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 84872404646     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.12.012     Document Type: Article

References (41)

1. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004, 4:806-813.
2. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
3. Lunt S.J., Fyles A., Hill R.P., Milosevic M. Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis. Future Oncol 2008, 4:793-802.
4. Ferretti S., Allegrini P.R., Becquet M.M., McSheehy P.M. Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics. Neoplasia 2009, 11:874-881.
5. Zhang L., Yao H.J., Yu Y., Zhang Y., Li R.J., Ju R.J., et al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 2012, 33:565-582.
6. Wang Z., Yu Y., Dai W., Lu J., Cui J., Wu H., et al. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer. Biomaterials 2012, 33:8451-8460.
7. Ellerhorst J.A., Bedikian A., Ring S., Buzaid A.C., Eton O., Legha S.S. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Oncol Rep 1999, 6:1097-1099.
8. Smylie M.G., Wong R., Mihalcioiu C., Lee C., Pouliot J.F. A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma. Invest New Drugs 2007, 25:155-159.
9. Kato M., Hattori Y., Kubo M., Maitani Y. Collagenase-1 injection improved tumor distribution and gene expression of cationic lipoplex. Int J Pharm 2012, 423:428-434.
10. Ohta M., Kawabata T., Yamamoto M., Tanaka T., Kikuchi H., Hiramatsu Y., et al. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surg Today 2009, 39:1046-1053.
11. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
12. Pietras K., Ostman A., Sjöquist M., Buchdunger E., Reed R.K., Heldin C.H., et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001, 61:2929-2934.
13. Vlahovic G., Rabbani Z.N., Herndon J.E., Dewhirst M.W., Vujaskovic Z. Treatment with imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer 2006, 95:1013-1019.
14. Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002, 1:493-502.
15. Pietras K., Rubin K., Sjöblom T., Buchdunger E., Sjöquist M., Heldin C.H., et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002, 62:5476-5484.
16. Vlahovic G., Ponce A.M., Rabbani Z., Salahuddin F.K., Zgonjanin L., Spasojevic I., et al. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 2007, 97:735-740.
17. Zhang J., Jin W., Wang X., Wang J., Zhang X., Zhang Q. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol Pharm 2010, 7:1159-1168.
18. Wiig H., Reed R.K., Aukland K. Measurement of interstitial fluid pressure: comparison of methods. Ann Biomed Eng 1986, 14:139-151.
19. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1:1112-1116.
20. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681.
21. Triozzi P.L., Aldrich W., Dombos C. Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo. Melanoma Res 2008, 18:420-430.
22. Baranowska-Kortylewicz J., Abe M., Pietras K., Kortylewicz Z.P., Kurizaki T., Nearman J., et al. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res 2005, 65:7824-7831.
23. Faber E., Nausová J., Jarosová M., Egorin M.J., Holzerová M., Rozmanová S., et al. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing. Leuk Lymphoma 2006, 47:1082-1090.
24. Pietras K., Stumm M., Hubert M., Buchdunger E., Rubin K., Heldin C.H., et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003, 9:3779-3787.
25. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003, 200:500-503.
26. Gallagher P.G., Bao Y., Prorock A., Zigrino P., Nischt R., Politi V., et al. Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumor interactions in metastasis. Cancer Res 2005, 65:4134-4146.
27. Pietras K., Pahler J., Bergers G., Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008, 5:e19.
28. Sandler C., Joutsiniemi S., Lindstedt K.A., Juutilainen T., Kovanen P.T., Eklund K.K. Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 2006, 347:31-35.
29. Kimura Y., Inoue K., Abe M., Nearman J., Baranowska-Kortylewicz J. PDGFRbeta and HIF-1alpha inhibition with imatinib and radioimmunotherapy of experimental prostate cancer. Cancer Biol Ther 2007, 6:1763-1772.
30. Prakash J., de Jong E., Post E., Gouw A.S., Beljaars L., Poelstra K. A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier. J Control Release 2010, 145:91-101.
31. Board R., Jayson G.C. Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist Updat 2005, 8:75-83.
32. Furuhashi M., Sjöblom T., Abramsson A., Ellingsen J., Micke P., Li H., et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 2004, 64:2725-2733.
33. Pietras K., Sjöblom T., Rubin K., Heldin C.H., Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003, 3:439-443.
34. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731-3736.
35. Sharma P., Brown S., Walter G., Santra S., Moudgil B. Nanoparticles for bioimaging. Adv Colloid Interface Sci 2006, 123-126:471-485.
36. Xiang Y., Liang L., Wang X., Wang J., Zhang X., Zhang Q. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. J Control Release 2011, 152:402-410.
37. Schädlich A., Rose C., Kuntsche J., Caysa H., Mueller T., Göpferich A. How stealthy are PEG-PLA nanoparticles? An NIR in vivo study combined with detailed size measurements. Pharm Res 2011, 28:1995-2007.
38. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994, 54:3352-3356.
39. Chauhan V.P., Stylianopoulos T., Martin J.D., Popović Z., Chen O., Kamoun W.S., et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012, 7:383-388.
40. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56:185-229.
41. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446.